Navigation Links
Ventas Completes Previously Announced Sale of Common Stock

Company Receives Net Proceeds of $191.9 Million

LOUISVILLE, Ky., Feb. 1 /PRNewswire-FirstCall/ -- Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company") announced today that it has completed the sale of 4,485,000 shares of its common stock pursuant to the Company's existing shelf registration statement. The amount includes 585,000 shares of common stock that were sold pursuant to the exercise of the underwriter's overallotment option. The Company received net proceeds, before expenses, of $191.9 million, which the Company will use to repay indebtedness outstanding under its revolving credit facility and for working capital and other general corporate purposes, including to fund future acquisitions. As previously announced, the shares were sold to UBS Investment Bank, as sole underwriter, at a price of $42.78 per share.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Ventas, Inc. is a leading healthcare real estate investment trust. Its diverse portfolio of properties located in 43 states and two Canadian provinces includes seniors housing communities, skilled nursing facilities, hospitals and medical office and other properties.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Ventas, Inc.'s ("Ventas" or the "Company") and its subsidiaries' expected future financial position, results of operations, cash flows, funds from operations, dividends and dividend plans, financing plans, business strategy, budgets, projected costs, capital expenditures, competitive positions, acquisitions, investment opportunities, merger integration, growth opportunities, expected lease income, continued qualification as a real estate investment trust ("REIT"), plans and objectives of management for future operations and statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will" and other similar expressions are forward-looking statements. Such forward-looking statements are inherently uncertain, and security holders must recognize that actual results may differ from the Company's expectations. The Company does not undertake a duty to update such forward-looking statements, which speak only as of the date on which they are made.

The Company's actual future results and trends may differ materially depending on a variety of factors discussed in the Company's filings with the Securities and Exchange Commission. Factors that may affect the Company's plans or results include without limitation: (a) the ability and willingness of the Company's operators, tenants, borrowers, managers and other third parties, as applicable, to meet and/or perform the obligations under their various contractual arrangements with the Company; (b) the ability and willingness of Kindred Healthcare, Inc. (together with its subsidiaries, "Kindred"), Brookdale Living Communities, Inc. (together with its subsidiaries, "Brookdale") and Alterra Healthcare Corporation (together with its subsidiaries, "Alterra") to meet and/or perform their obligations to indemnify, defend and hold the Company harmless from and against various claims, litigation and liabilities under the Company's respective contractual arrangements with Kindred, Brookdale and Alterra; (c) the ability of the Company's operators, tenants, borrowers and managers, as applicable, to maintain the financial strength and liquidity necessary to satisfy their respective obligations and liabilities to third parties, including without limitation obligations under their existing credit facilities; (d) the Company's success in implementing its business strategy and the Company's ability to identify, underwrite, finance, consummate and integrate diversifying acquisitions or investments, including those in different asset types and outside the United States; (e) the nature and extent of future competition; (f) the extent of future or pending healthcare reform and regulation, including cost containment measures and changes in reimbursement policies, procedures and rates; (g) increases in the Company's cost of borrowing; (h) the ability of the Company's operators and managers, as applicable, to deliver high quality services, to attract and retain qualified personnel and to attract residents and patients; (i) the results of litigation affecting the Company; (j) changes in general economic conditions and/or economic conditions in the markets in which the Company may, from time to time, compete; (k) the Company's ability to pay down, refinance, restructure and/or extend its indebtedness as it becomes due; (l) the movement of interest rates and the resulting impact on the value of and the accounting for the Company's interest rate swap agreement; (m) the Company's ability and willingness to maintain its qualification as a REIT due to economic, market, legal, tax or other considerations; (n) final determination of the Company's taxable net income for the year ended December 31, 2007; (o) the ability and willingness of the Company's tenants to renew their leases with the Company upon expiration of the leases and the Company's ability to relet its properties on the same or better terms in the event such leases expire and are not renewed by the existing tenants; (p) risks associated with the acquisition of Sunrise Senior Living REIT ("Sunrise REIT"), including the timely delivery of accurate property-level financial results for the Company's properties and the Company's ability to timely and fully realize the expected revenues and cost savings therefrom; (q) factors causing volatility in the Company's revenues generated by the properties acquired in connection with the acquisition of Sunrise REIT, including without limitation national and regional economic conditions, costs of materials, energy, labor and services, employee benefit costs and professional and general liability claims; (r) the movement of U.S. and Canadian exchange rates; (s) year-over-year changes in the Consumer Price Index and the effect of those changes on the rent escalators, including the rent escalator for Master Lease 2 with Kindred, and the Company's earnings; (t) the impact on the liquidity, financial condition and results of operations of the Company's operators, tenants, borrowers and managers, as applicable, resulting from increased operating costs and uninsured liabilities for professional liability claims, and the ability of the Company's operators, tenants, borrowers and managers to accurately estimate the magnitude of such liabilities; and (u) the impact of the Sunrise Senior Living, Inc. strategic review process and accounting, legal and regulatory issues. Many of these factors are beyond the control of the Company and its management.

Contacts: Debra A. Cafaro

Chairman, President and CEO


Richard A. Schweinhart

Executive Vice President and CFO

(502) 357-9000

SOURCE Ventas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
2. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
3. Ventas Announces 2007 Third Quarter Earnings Release Date and Conference Call
4. Ventas Appoints Brush SVP - Senior Housing Development and Operations
5. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
6. Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance
7. Ventas Enters Agreement to Sell Common Stock
8. Eligard(R) six-month formulation successfully completes European approval procedure
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
11. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
Post Your Comments:
(Date:12/1/2015)... ... , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won ... order will be from the China Disabled Persons’ Federation, a central government association, for ... for children and adults suffering from severe and profound hearing loss . The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., ... Provider (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the ... Center solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Trevor and Taylor Crabb have unveiled an exciting ... chance to represent the United States. This hybrid crowdfunding campaign is designed ... their journey in addition to offering corporate sponsors with some great marketing deliverables with ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association of Professional ... VIP Woman of the Year Circle. She is recognized with this prestigious distinction for ... for professional women, boasting more than 850,000 members and over 200 operating Local Chapters. ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- MEDTEC Japan 2016, Asia,s largest exhibition and conference ... in Tokyo from 20 th  - 22 nd April 2016. ...   --> -->   ... . With the aging population and the government back up, the Medical ... the United States . With the aging population and the ...
(Date:11/30/2015)... , Nov. 30, 2015 Nevro Corp. (NYSE: ... innovative evidence-based solutions for the treatment of chronic pain, today ... the U.S. Patent and Trademark Office (USPTO) has denied instituting ... No. 8,359,102 (the ,102 patent).  --> ... of Boston Scientific Corporation filed two petitions challenging the validity ...
(Date:11/30/2015)... ) has ... Market 2015-2019" report to their offering. ... of the "Orphan Drugs Market 2015-2019" ... and Markets ( ) has announced the ... report to their offering. ...
Breaking Medicine Technology: